Lonza Group restates 2025 half-year figures, shares in focus on SIX Swiss Exchange
23.06.2026 - 20:38:55 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 20:36.
Lonza Group AG (CH0013841017) has restated its Half-Year 2025 financials to present its Capsules & Health Ingredients activities as discontinued operations, according to an ad hoc announcement published on SIX Swiss Exchange on 23 June 2026. The Swiss contract development and manufacturing group remains a heavyweight on the SIX platform and in the SMIM mid-cap index as investors digest the revised data ahead of the July earnings date. Lonza ad hoc statement of 23 June 2026
What the restatement changes
In the Art. 53 LR ad hoc release, Lonza states that the Half-Year 2025 figures have been recast so that Capsules & Health Ingredients, often abbreviated as CHI, are now reported under discontinued operations, in line with the Full-Year 2025 presentation following the divestment decision taken in December 2024. The company explains that the restatement covers the consolidated income statement and selected key performance measures for the comparative period, while leaving previously reported Full-Year 2025 results unchanged. EQS ad hoc text via Deutsche Börse
Lonza links the timing of the restatement to its upcoming Half-Year 2026 results, scheduled for 22 July 2026, so that investors on SIX Swiss Exchange and in key indices such as the SPI and SMIM can compare continuing operations on a consistent basis. The group underscores that the updated presentation focuses attention on its core biologics and small-molecules CDMO activities, which form the operational backbone after the strategic repositioning. Financial Times company announcement extract
Strategic context and CHI divestment
The restatement follows Lonza’s plan to divest the CHI business, first communicated in December 2024, which shifted the historically integrated capsules and health ingredients activities into non-core status within the portfolio. On 6 March 2026, Lonza signed a definitive agreement to sell CHI to Lone Star Funds, with closing targeted for the third quarter of 2026 subject to customary conditions, reinforcing the pivot toward pure-play CDMO services. Lonza transaction timeline in the ad hoc release
For analysts tracking European life-sciences tools peers such as Sartorius and Siegfried, the removal of CHI from continuing operations simplifies margin and growth comparisons by stripping out a business with different capital intensity and demand patterns. Consensus compilations on platforms like MarketScreener show that a majority of covering houses still rate Lonza shares positively, reflecting expectations that the streamlined group can drive higher returns in its biologics and cell-and-gene manufacturing franchises. MarketScreener analyst consensus overview
All news and key data on the Lonza Group shares
Charts, historical announcements and further analyst views help investors assess how the Lonza Group shares trade around the CHI restatement and the upcoming Half-Year 2026 figures.
How Lonza earns its money
Lonza’s core business today is contract development and manufacturing for the biopharmaceutical industry, with a strong focus on mammalian and microbial biologics, small molecules and advanced therapies such as cell and gene treatments. The group also runs a network of global development and manufacturing sites that provide custom services from early-stage process development through to commercial-scale production for pharma and biotech clients.
Where the Lonza shares trade now
The Lonza Group AG shares (CH0013841017) last traded on SIX Swiss Exchange at 538.00 Swiss francs as of 2026-06-23, 09:30.
Key data on the Lonza Group shares
- Company: Lonza Group AG
- ISIN: CH0013841017
- WKN: 928619
- Ticker: LONN
- Trading venue: SIX Swiss Exchange
- Price (as of 2026-06-23, 09:30): 538.00 CHF
- Market cap: 40.5 billion CHF (as of 2026-06-23)
- Sector / industry: Healthcare - Life Sciences Tools & Services / CDMO
- Index membership: SPI, SMIM
- Next earnings date: 2026-07-22
This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. All information has been carefully researched but cannot be guaranteed for accuracy or completeness. Investors should conduct their own research or consult a professional advisor before making investment decisions.
